Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary

Seagen Inc. (SGEN) announced the presentation of new data for ADCETRIS (brentuximab vedotin) at the upcoming American Society of Hematology Annual Meeting from December 11-14, 2021. This includes five oral presentations and updates on its efficacy and safety in treating various lymphomas. Notably, initial results from the SEA-BCMA program, targeting relapsed/refractory multiple myeloma, will also be shared. ADCETRIS is approved in over 75 countries for specific lymphoma types, emphasizing its significance in oncology.

Positive

• Presentation of 19 abstracts showcasing progress in novel combinations for ADCETRIS.
• Five oral presentations planned at a major hematology conference.
• Updated safety and efficacy results for ADCETRIS in multiple lymphoma types.
• Initial results from the SEA-BCMA program focusing on multiple myeloma.

Negative

• Potential risks related to clinical trials as indicated in forward-looking statements.

- Data From 19 Abstracts, Including Five Oral Presentations Demonstrate Progress in Novel Combinations and Across Multiple Settings in Lymphoma and Other Indications –

BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq:SGEN) today announced that new data for ADCETRIS® (brentuximab vedotin), including five oral presentations, will be featured at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021. Data presentations will include updated safety and efficacy results from clinical trials examining the potential of ADCETRIS with novel combinations in patients with advanced stage classical Hodgkin lymphoma (HL), in patients with newly diagnosed CD30-expressing peripheral T-cell lymphoma (PTCL) and in patients with other histologies.

“We look forward to sharing new data for the continued development of ADCETRIS in combination with other therapies across patient populations,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “Additionally, initial results will be presented from our SEA-BCMA program in patients with relapsed/refractory multiple myeloma.”

ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and expressed on the surface of several types of PTCL. ADCETRIS is approved in more than 75 countries for relapsed or refractory HL and systemic anaplastic large cell lymphoma (sALCL).

Presentations of Company-Sponsored ADCETRIS Trials:

Abstract Title	Abstract #	Presentation	Lead Author
The ECHELON-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma	#135	Oral presentation / Saturday, Dec. 11, 12:00 – 1:30 p.m. EST	S. Horwitz
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens	#1390	Poster presentation / Saturday, Dec. 11, 5:30 – 7:30 p.m. EST	S. Parsons
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)—a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age	#1966	Poster presentation / Saturday, Dec. 11, 5:30 – 7:30 p.m. EST	D. Flora
Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma	#1197	Poster presentation / Saturday, Dec. 11, 5:30 – 7:30 p.m. EST	D. Taft
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary results from the single-arm phase 2 study (SGN35-027 Part B)	#2454	Poster presentation / Sunday, Dec. 12, 6:00 – 8:00 p.m. EST	H. Lee
An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective	#2440	Poster presentation / Sunday, Dec. 12, 6:00 – 8:00 p.m. EST	T. Phillips
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma	#2467	Poster presentation / Sunday, Dec. 12, 6:00 – 8:00 p.m. EST	A. Evens
An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective	#2466	Poster presentation / Sunday, Dec. 12, 6:00 – 8:00 p.m. EST	J. Burke
SEA-BCMA, an investigational nonfucosylated monoclonal antibody: interim results of a phase 1 study in relapsed/refractory multiple myeloma patients (SGNBCMA-001)	#2740	Poster presentation / Sunday, Dec. 12, 6:00 – 8:00 p.m. EST	J. Hoffman
Trials-In-Progress
Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)	#1369	Poster presentation / Saturday, Dec. 11, 5:30 – 7:30 p.m. EST	I. Flinn
Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)	#3564	Poster presentation / Monday, Dec. 13, 6:00 – 8:00 p.m. EST	N. Bartlett
Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients With Peripheral T Cell Lymphoma With Less Than 10% CD30 Expression (SGN35 032, Trial in Progress)	#1401	Poster presentation / Saturday, Dec. 11, 5:30 – 7:30 p.m. EST	D. Jagadeesh

Presentations of Investigator-Sponsored and Cooperative Group ADCETRIS Trials:

Abstract Title	Abstract #	Presentation	Lead Author
Brentuximab vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Expressing Peripheral T-cell Lymphomas	#133	Oral presentation / Saturday, Dec. 11, 12:00 – 1:30 p.m. EST	A. Herrera
The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDTASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma	#136	Oral presentation / Saturday, Dec. 11, 12:00 – 1:30 p.m. EST	D. Sibon
Interim results of a multicenter pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia/lymphoma	#1395	Poster presentation / Saturday, Dec. 11, 5:30 – 7:30 p.m. EST	C. Dittus
Pacific: A Phase II Study of Brentuximab vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma	#1408	Poster presentation / Saturday, Dec. 11, 5:30 – 7:30 p.m. EST	R. Steiner
Brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP as salvage strategy for patients with primary refractory or relapsed classical Hodgkin’s Lymphoma. Preliminary results from the BRESELIBET prospective clinical	#2459	Poster presentation / Sunday, Dec. 12, 6:00 – 8:00 p.m. EST	A. Sureda
Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in 718 Patients with Relapsed/Refractory Hodgkin Lymphoma	#879	Oral presentation / Monday, Dec. 13, 6:15 – 7:45 p.m. EST	J. Driessen
The Evolution of Children’s Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity	#81	Oral presentation / Monday, Dec. 13, 6:15 – 7:45 p.m. EST	A. Lo

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of Seagen’s products and product candidates, the company’s pipeline and the advancement of its research and development activities. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials, the possibility of adverse regulatory actions, and the potential for delays or setbacks in product development and the regulatory review process. More information about the risks and uncertainties faced by the company is contained under the caption “Risk Factors” included in Seagen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005817/en/

For Media

David Caouette

Vice President, Corporate Communications

(310) 430-3476

dcaouette@seagen.com

For Investors

Peggy Pinkston

Senior Vice President, Investor Relations

(425) 527-4160

ppinkston@seagen.com

Source: Seagen Inc.

FAQ

What new data is Seagen presenting for SGEN at the ASH 2021 Annual Meeting?

Seagen is showcasing 19 abstracts, including five oral presentations on ADCETRIS, focusing on its efficacy and safety across various lymphomas.

What are the implications of the SEA-BCMA program results announced by Seagen?

Initial results from the SEA-BCMA program in relapsed/refractory multiple myeloma will be presented, indicating ongoing development in this indication.

How is ADCETRIS performing in clinical trials according to the latest news from Seagen?

ADCETRIS continues to show promising data in clinical trials with novel combinations, especially for advanced-stage classical Hodgkin lymphoma and peripheral T-cell lymphoma.

What safety and efficacy updates for ADCETRIS are expected during the ASH Annual Meeting?

The presentations will include updated safety and efficacy results from various clinical trials involving ADCETRIS.

When will Seagen present its findings at the ASH Annual Meeting?

Seagen's presentations are scheduled for December 11-14, 2021.